Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.71 |
| ▸ | PDE4A | P27815 | 13/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.64 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10178116 | 0.88 | PDE4A (0.81) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10178196 | 0.85 | ADORA2B (0.68) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10178241 | 0.84 | PDE4A (0.61) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| Acefylline SCHEMBL308514 | 0.84 | ADORA2B (1.00) | ADORA2BSMN1; SMN2 | |
| Acefylline SCHEMBL18191994 | 0.84 | ADORA2B (1.00) | ADORA2BSMN1; SMN2 | |
| Acefylline SCHEMBL8402147 | 0.82 | ADORA2B (0.97) | ADORA2BSMN1; SMN2 | |
| Acefylline SCHEMBL1173152 | 0.82 | ADORA2B (0.89) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| Acefylline SCHEMBL17204841 | 0.79 | ADORA2B (0.84) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29393229 | 0.78 | PDE4A (1.00) | ADORA2BPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10178114 | 0.78 | ADORA2B (0.73) | ADORA2BPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | ADORA2B 97/4885PDE4A 1161/4885PDE4B 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.